Vaccination for prevention of infectious diseases provides one of the most valuable and cost-effective clinical interventions. Despite recent progress in personalized cancer vaccines targeting patient specific tumor neoantigens, a breakthrough is urgently needed to make these technologies applicable to a broad spectrum of cancers. 

We are challenging this unmet technical gap from a new concept designed to bypass the use of mRNAs for targeting individual cancer specific antigens. Based on a technology designed to selectively introduce a target antigen into cancer cells, we are developing a small molecule-based cancer vaccine. This approach holds a great potential to create a universal vaccine applicable to a broad spectrum of cancers. 

Successful development of the totally small molecule-based, broadly applicable cancer vaccine should have a major impact on cancer therapy, providing an effective and low-cost treatment option beneficial to a large number of patients.